Shenandoah

The company's primary focus is on developing a new class of molecules known as Transcriptional Chemical Inducers of Proximity (TCIPs). This platform technology operates by artificially linking two specific proteins within a cancer cell. One protein is essential for the cancer cell's survival, while the other activates cell death genes. By bringing these proteins together, the TCIPs effectively rewire the cell's own machinery, turning a dependency for survival into a mechanism for its destruction. This gain-of-function approach departs from traditional methods that focus on blocking protein functions.

Shenandoah's business model centers on the discovery and preclinical development of these novel therapeutic solutions to address unmet medical needs. The company's initial program targets a protein called BCL6, a key driver in lymphoma, aiming to convert it from a survival factor into a cell death trigger. The goal is to advance these proprietary molecules through preclinical testing to gather sufficient data to support future clinical trials. Headquartered in South San Francisco, California, the company operates within the competitive biotechnology sector, specifically in discovery tools for healthcare. To fuel its research and development, Shenandoah Therapeutics secured $21.5 million in a seed funding round co-led by Samsara BioCapital and YK Bioventures, with participation from First Spark Ventures and Time BioVentures.